PT  - JOURNAL ARTICLE
AU  - C Echevarria
AU  - J Steer
AU  - K Heslop-Marshall
AU  - S C Stenton
AU  - P M Hickey
AU  - R Hughes
AU  - M Wijesinghe
AU  - R N Harrison
AU  - N Steen
AU  - A J Simpson
AU  - G J Gibson
AU  - S C Bourke
TI  - The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPD
AID  - 10.1136/thoraxjnl-2016-209298
DP  - 2017 Aug 01
TA  - Thorax
PG  - 686--693
VI  - 72
IP  - 8
4099  - http://thorax.bmj.com/content/72/8/686.short
4100  - http://thorax.bmj.com/content/72/8/686.full
SO  - Thorax2017 Aug 01; 72
AB  - Background One in three patients hospitalised due to acute exacerbation of COPD (AECOPD) is readmitted within 90 days. No tool has been developed specifically in this population to predict readmission or death. Clinicians are unable to identify patients at particular risk, yet resources to prevent readmission are allocated based on clinical judgement.Methods In participating hospitals, consecutive admissions of patients with AECOPD were identified by screening wards and reviewing coding records. A tool to predict 90-day readmission or death without readmission was developed in two hospitals (the derivation cohort) and validated in: (a) the same hospitals at a later timeframe (internal validation cohort) and (b) four further UK hospitals (external validation cohort). Performance was compared with ADO, BODEX, CODEX, DOSE and LACE scores.Results Of 2417 patients, 936 were readmitted or died within 90 days of discharge. The five independent variables in the final model were: Previous admissions, eMRCD score, Age, Right-sided heart failure and Left-sided heart failure (PEARL). The PEARL score was consistently discriminative and accurate with a c-statistic of 0.73, 0.68 and 0.70 in the derivation, internal validation and external validation cohorts. Higher PEARL scores were associated with a shorter time to readmission.Conclusions The PEARL score is a simple tool that can effectively stratify patients' risk of 90-day readmission or death, which could help guide readmission avoidance strategies within the clinical and research setting. It is superior to other scores that have been used in this population.Trial registration number UKCRN ID 14214.